Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 20,000 shares of the firm's stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average price of $4.92 per share, with a total value of $98,400.00. Following the completion of the acquisition, the chief executive officer now owns 3,266,424 shares in the company, valued at $16,070,806.08. The trade was a 0.62 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Nuvectis Pharma Price Performance
Shares of NVCT traded up $0.09 on Monday, reaching $5.04. The company's stock had a trading volume of 281,541 shares, compared to its average volume of 118,220. Nuvectis Pharma, Inc. has a 12-month low of $4.82 and a 12-month high of $12.10. The stock has a market capitalization of $97.37 million, a P/E ratio of -4.46 and a beta of 0.41. The stock's 50 day simple moving average is $7.13 and its two-hundred day simple moving average is $6.80.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same quarter in the prior year, the company posted ($0.37) EPS. Analysts expect that Nuvectis Pharma, Inc. will post -1.03 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a report on Tuesday, August 6th.
Check Out Our Latest Report on NVCT
Hedge Funds Weigh In On Nuvectis Pharma
Large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its position in shares of Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock valued at $315,000 after purchasing an additional 1,790 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Nuvectis Pharma by 1.5% in the first quarter. Vanguard Group Inc. now owns 298,800 shares of the company's stock worth $2,450,000 after buying an additional 4,517 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Nuvectis Pharma during the second quarter worth $58,000. Nations Financial Group Inc. IA ADV purchased a new position in Nuvectis Pharma during the third quarter valued at $63,000. Finally, Baxter Bros Inc. bought a new stake in Nuvectis Pharma in the 2nd quarter valued at $79,000. Hedge funds and other institutional investors own 96.77% of the company's stock.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Read More
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
